

REMARKS/ARGUMENTS

Interview Summary

A telephonic interview was conducted on or about Feb. 11, 2008 with Examiner Zeman. Enablement of the scope of the method claims was discussed, regarding the term “antigen presenting cell” and the diseases or disorders being treated. This supplemental response is filed in response.

Claim Amendments

The claims have been amended to better clarify the invention. Support for the amendments can be found throughout the application as filed, including in the Examples and as shown in the drawings. No new matter is added.

Support for the amendments reciting that the antigen-presenting cell is a dendritic cell can be found in the Examples and in claims 2, 6, 9, 12, 15, 19 and 28-29 as filed.

Support for the amendments reciting that method of increasing the expression of interleukin 10 (IL10) in a mammal can be found in paragraph 0002 (“The present invention also provides a process for preparing novel synthetic SPAs that can be used to induce the activity of T regulatory cells and the expression of interleukin 10 (IL10) in humans and other animals”), in paragraphs 0010, 0047 (and Figure 3), 0079, 0081, 0091, 0093, 0105, and in Examples 2 and 6 (see page 68-70 and Table 6: up-regulation of IL10 was “[a]lso seen with Compound 15 @ 100 ug/ml”).

Support for methods of treating or preventing abscess and sepsis using compound 15 (new claims 34-40 and 42-44) is found throughout the application as filed, including in Example 13 at pages 70-72, where administration of CP1 and Compound 15 were shown to decrease the percent of animals with abscesses in a dose-dependent fashion. Additionally, it was stated that “nor do these animals display symptoms of sepsis” (page 71, lines 29-30). As discussed during the telephonic interview, the rat model presented in Example 13 is also used as a model for sepsis, and therefore this example also provides a working example of treating or preventing sepsis. A reference demonstrating use of this rat model as a model for sepsis is attached.

Support for methods of treating or preventing post-surgical adhesions using compound 15 (new claims 34-40 and 42-44) is found throughout the application as filed, including in Example 15 at pages 72-75 (sic, now Example 14 as amended), where administration of CP1 and Compound 15 were shown to decrease the mean adhesion score in an animal model of post-surgical adhesions.

Support for new claim 41 can be found throughout the application, for example at page 34 line 24-page 35 line 25, and at page 33 lines 26-27, and in Example 1 regarding the synthesis and purification of Compound 15.

CONCLUSION

It is respectfully submitted that the above-identified application is now in condition for favourable consideration of all the claims, and prompt allowance of these claims is respectfully requested. Should the Examiner believe that anything further is desirable in order to place the application in better condition for allowance, the Examiner is invited to contact the applicant's undersigned attorney at the telephone number listed below.

Respectfully submitted

/David W. Maher/
David W. Maher
Reg. No. 40077
858-228-7829